Mylan to produce generic hepatitis therapy for developing countries

Mylan has signed a drug development deal with the Medicines Patent Pool with the aim of expanding access to chronic hepatitis C medicines in developing countries.

Under the terms of the deal, Mylan will produce and market a generic version of the hepatitis drug daclatasvir, originally created by Bristol-Myers Squibb, for distribution in 112 low and middle-income countries.

The tablet-based treatment is designed for use alongside sofosbuvir, with or without ribavirin, for the treatment of patients with chronic hepatitis C virus genotype 1 or genotype 3 infections in the US, or for genotypes 1, 3 and 4 in Europe.

With this new license, Mylan will be able to develop fixed-dose combinations that offer the potential to treat all of the six major genotypes of the disease.

Rajiv Malik, Mylan's president, said: "We're committed at Mylan to reducing the burden of hepatitis C on communities around the world by providing access to high-quality medicines that treat the disease."

This comes after the World Health Organization added several new hepatitis C treatments, including daclatasvir, to its essential medicines list, in order to help promote equitable access to innovative medicines.

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.